Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation.

Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA.

Cancer Biol Ther. 2007 Feb;6(2):228-36. Epub 2007 Feb 25.

PMID:
17218785
2.
3.

Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.

Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T.

Int J Oncol. 2004 Apr;24(4):821-7.

PMID:
15010818
4.

Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase.

Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey D, Newman RA.

Prostate. 2003 Jun 1;55(4):281-91.

PMID:
12712407
5.
8.

Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.

Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G, Zunino F.

Prostate. 2001 Sep 15;48(4):254-64.

PMID:
11536305
10.

5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.

Matsuyama M, Yoshimura R, Mitsuhashi M, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T.

Oncol Rep. 2005 Jul;14(1):73-9.

PMID:
15944770
11.

Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells.

Jankun J, Aleem AM, Malgorzewicz S, Szkudlarek M, Zavodszky MI, Dewitt DL, Feig M, Selman SH, Skrzypczak-Jankun E.

Mol Cancer Ther. 2006 May;5(5):1371-82.

12.

Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.

Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R, Sette C.

Carcinogenesis. 2008 Dec;29(12):2279-88. doi: 10.1093/carcin/bgn221. Epub 2008 Sep 22.

PMID:
18809972
13.

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):918-25.

14.
15.
16.

Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.

Wang P, Liu B, Luo JD, Zhang ZG, Ma Q, Chen ZD.

Asian J Androl. 2007 May;9(3):353-60.

17.

[DMF induces apoptosis in human androgen-independent prostate cancer PC3 cells in vitro].

Fang YF, Liu T, Cao J.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 May;36(3):255-60. Chinese.

PMID:
17571308
18.

Relationship between lipoxygenase and human testicular cancer.

Yoshimura R, Matsuyama M, Mitsuhashi M, Takemoto Y, Tsuchida K, Kawahito Y, Sano H, Nakatani T.

Int J Mol Med. 2004 Mar;13(3):389-93.

PMID:
14767568
19.

Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.

Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N, Jisaka M, Boeglin WE, Vader V, Dave DS, Shook MF, Thomas TZ, Funk CD, Brash AR, Matusik RJ.

Cancer Res. 2003 May 1;63(9):2256-67.

20.

New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.

Pommery N, Taverne T, Telliez A, Goossens L, Charlier C, Pommery J, Goossens JF, Houssin R, Durant F, Hénichart JP.

J Med Chem. 2004 Dec 2;47(25):6195-206.

PMID:
15566290

Supplemental Content

Support Center